EMA Authorised: Pyrukynd (mitapivat sulfate) — Agios Netherlands B.V.

View source ↗

Summary

Pyrukynd (mitapivat sulfate) has been authorised in the EU for genetic diseases inborn and hemolytic anemia, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Diseases Inborn
• Hemolytic Anemia

Drugs mentioned

• Pyrukynd (mitapivat)

Snippet

Status: Authorised. Therapeutic area: Genetic Diseases, Inborn;Anemia, Hemolytic. MAH: Agios Netherlands B.V.. Decision date: 21/05/2026. Orphan medicine